Long term safety of romiplostim in patients with immune thrombocytopenia in Nordic countries: Nordic Country Patient Registry for Immune Thrombocytopenia (NCPRITP)

Trial Profile

Long term safety of romiplostim in patients with immune thrombocytopenia in Nordic countries: Nordic Country Patient Registry for Immune Thrombocytopenia (NCPRITP)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 30 Aug 2017 According to trial design presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, 3749 patients have been enrolled.
    • 30 Aug 2017 Trial design presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top